Allogene Therapeutics (ALLO) Retained Earnings (2018 - 2026)
Allogene Therapeutics (ALLO) posted Retained Earnings of -$183000.0 for Q1 2026, up 99.99% sequentially from -$2.0 billion in Q4 2025, and up 99.99% YoY from -$91504.5 in Q1 2025.
Allogene Therapeutics (ALLO) Retained Earnings (2018 - 2026) Analysis & Trends
Allogene Therapeutics has reported Retained Earnings for 9 years, with the latest figure at -$183000.0 in Q1 2026.
- Quarterly Retained Earnings rose 99.99% year-over-year to -$183000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$183000.0 (up 99.99% YoY) and the FY2025 annual result came in at -$2.0 billion, down 2259123.6% from the prior year.
- Retained Earnings improved to -$183000.0 in Q1 2026 per ALLO's latest filing, from -$2.0 billion in the prior quarter.
- Over five years, Retained Earnings peaked at $157000.0 in Q3 2024 and troughed at -$2.0 billion in Q4 2025.
- A 5-year average of -$949.9 million and a median of -$1.1 billion in 2022 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2024 and 2025: Retained Earnings jumped 106.51% in 2024, then sank 2259123.6% in 2025.
- Over 5 years, Retained Earnings stood at -$9.9 million in 2022, then sank by 15638.8% to -$1.6 billion in 2023, then surged by 99.99% to -$89000.0 in 2024, then tumbled by 2259123.6% to -$2.0 billion in 2025, then soared by 99.99% to -$183000.0 in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$183000.0, -$2.0 billion, and -$2.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Allogene Therapeutics | 707.96 Mn | 707.96 Mn | - | -2.10 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.10 Bn |
| Mar 31, 2026 | -183,000.00 |
| Dec 31, 2025 | -2.01 Bn |
| Sep 30, 2025 | -1.97 Bn |
| Jun 30, 2025 | -1.93 Bn |
| Mar 31, 2025 | -1.88 Bn |
| Dec 31, 2024 | -89,000.00 |
| Sep 30, 2024 | 157,000.00 |
| Jun 30, 2024 | -1.69 Bn |
| Mar 31, 2024 | -1.63 Bn |
| Dec 31, 2023 | -1.56 Bn |
| Sep 30, 2023 | -2.41 Mn |
| Jun 30, 2023 | -1.41 Bn |
| Mar 31, 2023 | -5.93 Mn |
| Dec 31, 2022 | -9.93 Mn |
| Sep 30, 2022 | -12.96 Mn |
| Jun 30, 2022 | -1.05 Bn |
| Mar 31, 2022 | -973.16 Mn |
| Dec 31, 2021 | -2.57 Mn |
| Sep 30, 2021 | -398,000.00 |